Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide in pediatric heterozygous familial hypercholesterolemia
NL-OMON59462Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enlicitide in familial hypercholesterolemia (FH) (5 arms), sponsored by Merck & Co. Primary endpoints: Maximum plasma concentration of enlicitide, Area under the concentration-time curve from 0 to 24 hours and 3 more. Started Feb 2026; status: recruiting.
02
Drugs
enlicitide
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON59462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59462.